# Model Card

## Model Name

Early-Phase Clinical Biomarker Exploratory Models

## Model Type

This project contains a small set of exploratory statistical and machine learning models developed on simulated early-phase oncology trial data:
- logistic regression for responder prediction,
- random forest for clinical benefit prediction,
- exploratory grouped survival association summaries.

These models are intended to support hypothesis generation and workflow demonstration rather than confirmatory or regulatory analysis.

## Intended Use

The models are intended to demonstrate how integrated clinical, biomarker, and PK variables can be used in an exploratory early development setting to:
- identify potential response-associated features,
- rank candidate predictors of clinical benefit,
- summarize relationships between biomarkers and outcome patterns.

Appropriate uses include:
- demonstration,
- educational purposes, presentation,
- prototype translational analytics workflows.

## Users

Intended users include:
- early development programmers,
- translational data scientists,
- biomarker scientists,
- clinical data scientists,
- evaluating workflow design and reproducibility.

## Input Features

The models use variables derived from the simulated integrated analysis dataset. Key inputs include:
- dose,
- age,
- ECOG,
- LDH,
- CRP,
- ctDNA fraction,
- AUC,
- Cmax,
- mutation status.

## Outputs

### Logistic regression
Predicts:
- responder status.

Output:
- probability of response,
- class prediction,
- feature coefficients.

### Random forest
Predicts:
- clinical benefit status.

Output:
- probability of clinical benefit,
- class prediction,
- feature importance ranking.

### Exploratory survival summary
Summarizes:
- median survival,
- event rate,
- grouped risk patterns.

## Training Data

All models were trained on fully simulated data generated to reflect a plausible early-phase oncology context. No real patient data were used.

The simulation intentionally encodes relationships such as:
- improved response with higher exposure,
- worse outcomes with elevated biomarkers,
- increasing toxicity with higher dose.

## Performance

Performance is reported only as an internal demonstration using the simulated dataset. Metrics such as ROC AUC and classification summaries are included to show workflow functionality rather than to establish real-world predictive validity.

Because the data are synthetic, performance should not be interpreted as clinically meaningful.

## Limitations

These models have several important limitations:
- they are trained on synthetic data,
- they are not validated on external datasets,
- they are not suitable for patient care or clinical decision-making,
- they are not developed under regulatory standards,
- they do not account for all complexities of real early-phase trial data.

## Ethical and Safety Considerations

The models must not be used for:
- treatment selection,
- dose selection in real patients,
- regulatory submissions,
- clinical risk prediction.

They are intended only as a programming and workflow demonstration.

## Reproducibility

Reproducibility is supported through:
- fixed random seeds,
- modular scripts,
- saved intermediate datasets,
- version-controllable code structure,
- explicit output generation.

## Maintenance

This model card should be updated if:
- additional models are added,
- real datasets are incorporated,
- new endpoints are introduced,
- performance evaluation methods change.
